Guardant Health, Inc. (GH)
NASDAQ: GH · IEX Real-Time Price · USD
19.10
+0.22 (1.17%)
May 6, 2024, 4:00 PM EDT - Market closed
Guardant Health Revenue
In the year 2023, Guardant Health had annual revenue of $563.95M with 25.45% growth. Revenue in the quarter ending December 31, 2023 was $155.05M with 22.19% year-over-year growth.
Revenue (ttm)
$563.95M
Revenue Growth
+25.45%
P/S Ratio
4.12
Revenue / Employee
$317,003
Employees
1,779
Market Cap
2.32B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 563.95M | 114.41M | 25.45% |
Dec 31, 2022 | 449.54M | 75.89M | 20.31% |
Dec 31, 2021 | 373.65M | 86.92M | 30.32% |
Dec 31, 2020 | 286.73M | 72.36M | 33.75% |
Dec 31, 2019 | 214.38M | 123.74M | 136.52% |
Dec 31, 2018 | 90.64M | 40.80M | 81.85% |
Dec 31, 2017 | 49.84M | 24.59M | 97.40% |
Dec 31, 2016 | 25.25M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Patterson Companies | 6.57B |
AMN Healthcare Services | 3.79B |
Integra LifeSciences Holdings | 1.54B |
Twist Bioscience | 277.49M |
Vericel | 197.52M |
RxSight | 89.08M |
Kymera Therapeutics | 79.41M |
Intellia Therapeutics | 36.28M |
GH News
- 14 days ago - FDA Advisory Panel Review of Guardant Health's Shield™ Blood Test to Screen for Colorectal Cancer to Be Held on May 23 - Business Wire
- 18 days ago - Guardant Health to Report First Quarter 2024 Financial Results on May 9, 2024 - Business Wire
- 4 weeks ago - Guardant Health to Present Data Highlighting Application of Epigenomics to Advance Precision Oncology at 2024 AACR Annual Meeting - Business Wire
- 7 weeks ago - Guardant Health ECLIPSE Study Data Demonstrating Efficacy of Shield Blood-based Test for Colorectal Cancer Screening to be Published in The New England Journal of Medicine - Business Wire
- 2 months ago - Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 2 months ago - New Survey: Patients and Physicians Overwhelmingly Agree Blood Tests Could Help Close the Colorectal Cancer Screening Gap - Business Wire
- 2 months ago - Guardant Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Outlook - Business Wire
- 2 months ago - Guardant Health to Participate in Upcoming Investor Conferences - Business Wire